T. Rowe Price Investment Management, Inc. Apellis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,605,721 shares of APLS stock, worth $177 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
4,605,721
Previous 6,303,584
26.93%
Holding current value
$177 Million
Previous $377 Million
28.25%
% of portfolio
0.17%
Previous 0.25%
Shares
7 transactions
Others Institutions Holding APLS
# of Institutions
337Shares Held
111MCall Options Held
1.26MPut Options Held
1.14M-
Wellington Management Group LLP Boston, MA15.1MShares$578 Million0.16% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.4MShares$436 Million19.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$426 Million7.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.51MShares$365 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$211 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $4.21B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...